⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Journal of Cancer Research and TherapeuticsOpen Access

Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin’s lymphoma

Ningjing Lin Chuan He Qingyuan Zhang Xiaonan Hong Lihong Liu Yang Shun-e Hang Su Xiaoyi Li Xiangrong Dai Yujie Li Jun Zhu

View Full Paper

Ask AI

Bookmark

Share

Abstract

The current treatment regimens for Hodgkin's lymphoma (HL) are associated with high incidences of adverse events.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lin et al. (2024) studied this question.

synapsesocial.com/papers/68e5e2bab6db6435875774c6 https://doi.org/10.4103/jcrt.jcrt_511_23

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1ABVD versus BEACOPP for front-line treatment of Hodgkin lymphoma: A systematic review and meta-analysis.RCT · 2026
2Evaluation of Acute and Early Cardiotoxicity in Survivors of Hodgkin's Disease Treated with ABVD or BEACOPP Regimenscohort · 2006 · 13 citations
3Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup TrialRCT · 2003 · 487 citations
4Treatment Strategies in Advanced-Stage Hodgkin Lymphoma2024 · 3 citations
5BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin LymphomaRCT · 2026 · 2 citations

More related papers

Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.2024
Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial2024

More from Journal of Cancer Research and Therapeutics

Regulation of tumor angiogenesis: Roles of lncRNAs in molecular signaling, microenvironmental remodeling, and anti-angiogenic therapyTue,
Cost-effectiveness of durvalumab consolidation therapy in limited-stage small-cell lung cancer: A Chinese and U.S. payer perspective analysisTue,